Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 22Neoplasms 5Neoplasm Metastasis 2Urachal cancer 1Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Cancer Metastatic 1Gastro-enteropancreatic neuroendocrine tumor 1Diabetes Mellitus, Insulin-Dependent, 12 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Borderline Resectable Pancreatic Cancer 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Oxaliplatin 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Surgical Procedures, Operative 1S 1 (combination) 1Leucovorin 1Gemcitabine 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Borderline Resectable Pancreatic Cancer × folfirinox × Clear all
NCT02717091 2020-09-10

Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer

Nagoya University

Phase 2 Unknown
50 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡